DCTH Delcath Systems, Inc. - Common Stock
NASDAQ · Health Care · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 6, 2026
$15.13
· % 处于52周区间
· 高于低点
· 至高点
$8.1252周低点
$17.4252周高点
市值 (MRQ)
$524M
P/E (TTM)
1513.0
EPS (TTM)
$0.01
收入 (TTM)
$95M
DCTH 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$15.13
市值 (MRQ)
$524M
P/E (TTM)
1513.0
EPS (TTM)
$0.01
收入 (TTM)
$95M
ROE (TTM)
0.47%
52周区间
$8–$17
DCTH 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2019年12月24日 | 1-for-700 | 反向 |
关于 Delcath Systems, Inc. - Common Stock 公司概况（来自维基百科）
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).
## Phase III melanoma trial enrolling
University of Pittsburgh Medical Center
National Cancer Institute in Bethesda, Maryland
Albany Medical Center in Albany, New York
John Wayne Cancer Center in Santa Monica, California
Moffitt Cancer Center in Tampa, Florida
Morristown Memorial Hospital in Morristown, New Jersey
Providence Cancer Center in Portland, Oregon
St. Luke's Cancer Center of Bethlehem, Pennsylvania
Swedish Medical Center in Englewood, Colorado
University of Maryland Medical Center in Baltimore, Maryland
University of Texas Medical Branch in Galveston, Texas
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Health Care
行业Health Care
员工156
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$85M2016-12-31 → 2025-12-31
EPS$0.072017-12-31 → 2025-12-31
自由现金流$21M2018-12-31 → 2025-12-31
净利率0.56%2022-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | DCTH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | 1513.05年均值 ≈25.4 | ≈25.4 | · | · | |
| P/S (TTM) | 5.55年均值 ≈17.7 | ≈17.7 | 3.7 | 估值过高 | |
| 市净率 (MRQ) | 4.35年均值 ≈3.0 | ≈3.0 | 3.4 | 估值过高 | |
| 股价/自由现金流 (TTM) | 29.95年均值 ≈-2.2 | ≈-2.2 | · | · | |
| 市现率 (TTM) | 26.85年均值 ≈-2.5 | ≈-2.5 | 18.5 | 低估 | |
| Price / Tangible Book (市净率（有形资产）) | 4.75年均值 ≈5.0 | ≈5.0 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | DCTH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 毛利率 (TTM) | 87.1%5年均值 ≈78.4% | ≈78.4% | 73.6% | 顶尖 | |
| 营业利润率 (TTM) | -1.9%5年均值 ≈-781.7% | ≈-781.7% | -8.2% | 顶尖 | |
| EBITDA Margin (息税折旧摊销前利润率) | 0.77%5年均值 ≈-781.7% | ≈-781.7% | -5.0% | 顶尖 | |
| 税前利润率 (TTM) | 1.4%5年均值 ≈-929.6% | ≈-929.6% | -11.3% | 顶尖 | |
| 净利润率 (TTM) | 0.56%5年均值 ≈-929.8% | ≈-929.8% | -13.1% | 顶尖 | |
| ROA (TTM) | 0.42%5年均值 ≈-86.2% | ≈-86.2% | -16.0% | 顶尖 | |
| ROE (TTM) | 0.47%5年均值 ≈27.9% | ≈27.9% | -25.7% | 顶尖 | |
| ROIC | 0.46%5年均值 ≈22.6% | ≈22.6% | -23.7% | 顶尖 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | DCTH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 9.85年均值 ≈6.3 | ≈6.3 | 3.5 | 流动性强 | |
| Quick Ratio (速动比率) | 5.05年均值 ≈3.5 | ≈3.5 | 2.2 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | DCTH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 129.1%5年均值 ≈445.8% | ≈445.8% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 215.3% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | DCTH | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.95年均值 ≈0.4 | ≈0.4 | 0.8 | 持平 | |
| Inventory Turnover (库存周转率) | 1.45年均值 ≈0.8 | ≈0.8 | 1.7 | 弱 | |
| Receivables Turnover (应收账款周转率) | 7.55年均值 ≈8.6 | ≈8.6 | 7.3 | 顶尖 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$546.4K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
88.6%
下次报告
十一月 02, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 10, 2026 | $0.07 | $-0.09 | 176.3% |
| 2026年3月31日 | 五月 12, 2026 | $-0.03 | $-0.09 | 66.1% |
| 2025年12月31日 | $-0.05 | $-0.06 | 20.5% | |
| 2025年9月30日 | $0.02 | $0.02 | -2.0% | |
| 2025年6月30日 | $0.07 | $0.03 | 174.5% | |
| 2025年3月31日 | $0.03 | $0.02 | 96.1% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85M | $37M | $2M | $3M | $4M | · | · | · | $3M | $2M | $2M | $1M | |
| Cost of Revenue | $12M | $6M | $635.0K | $686.0K | $671.0K | $640.0K | $719.0K | $1M | $701.0K | $550.0K | $462.0K | $291.0K | |
| Gross Profit | $73M | $31M | $1M | $2M | $3M | $1M | $861.0K | $2M | $2M | $1M | $1M | $778.0K | |
| R&D Expense | $29M | $14M | $18M | $19M | $14M | $11M | $9M | $20M | $10M | $8M | $6M | $4M | |
| SG&A Expense | $44M | $30M | $22M | $17M | $14M | $11M | $11M | $10M | $10M | $9M | $10M | $16M | |
| Operating Expenses | $73M | $43M | $40M | $36M | $27M | $22M | $21M | $29M | $20M | $18M | $16M | $20M | |
| Operating Income | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | $-18M | $-16M | $-15M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | · | $22M | $14M | $67.0K | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $17.0K | $9.0K | $5.0K | |
| Other Non-op | $-70.0K | $-30.0K | $-59.0K | $30.0K | $68.0K | $154.0K | $2.0K | $51.0K | $-41.0K | $17.0K | $9.0K | $-24.0K | |
| Pretax Income | $4M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Income Tax | $810.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| EPS (Basic) | $0.08 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| EPS (Diluted) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| Shares (Basic) | 35,821,157 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| Shares (Diluted) | 39,919,557 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| EBITDA | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | · | · | $-15M | $-19M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $32M | $13M | $8M | $23M | $29M | $10M | $3M | $4M | $4M | $13M | $20M | |
| Receivables | $12M | $11M | $241.0K | $366.0K | $44.0K | $57.0K | $21.0K | $585.0K | $317.0K | $403.0K | $277.0K | $174.0K | |
| Inventory | $10M | $7M | $3M | $2M | $1M | $855.0K | $654.0K | $858.0K | $1M | $660.0K | $757.0K | $349.0K | |
| Prepaid Expense | $6M | $3M | $1M | $2M | $3M | $3M | $2M | $898.0K | $700.0K | $698.0K | $960.0K | $974.0K | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $222.0K | |
| Current Assets | $120M | $74M | $37M | $16M | $31M | $32M | $13M | $6M | $8M | $34M | $15M | $22M | |
| PP&E (Net) | $3M | $2M | $1M | $1M | $1M | $1M | $735.0K | $925.0K | $1M | $1M | $1M | $2M | |
| PP&E (Gross) | $8M | $7M | $6M | $6M | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | |
| Total Assets | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Accounts Payable | $3M | $961.0K | $1M | $2M | $638.0K | $2M | $5M | $8M | $4M | $594.0K | $284.0K | $748.0K | |
| Accrued Liabilities | $8M | $5M | $5M | $5M | $4M | $5M | $7M | $8M | $3M | $3M | $2M | $4M | |
| Current Liabilities | $11M | $6M | $16M | $15M | $6M | $10M | $16M | $18M | $8M | $36M | $6M | $5M | |
| Capital Leases | $835.0K | $933.0K | $0 | · | $207.0K | $450.0K | $197.0K | $0 | · | · | · | · | |
| Other Non-current Liabilities | $628.0K | $766.0K | $840.0K | $1M | $207.0K | · | $0 | $628.0K | $395.0K | $604.0K | $820.0K | $1M | |
| Total Liabilities | $12M | $8M | $23M | $24M | $21M | $13M | $21M | $22M | $8M | $37M | $7M | $6M | |
| Long-term Debt | · | $0 | $10M | $16M | · | · | · | · | · | · | · | · | |
| Common Stock | $347.0K | $331.0K | $228.0K | $100.0K | $79.0K | $60.0K | $1.0K | $0 | $2.0K | $0 | $14.0K | $97.0K | |
| Paid-in Capital | $639M | $600M | $521M | $452M | $433M | $417M | $365M | $329M | $326M | $278M | $270M | $265M | |
| Retained Earnings | $-529M | $-532M | $-505M | $-457M | $-421M | $-395M | $-371M | $-344M | $-325M | $-279M | $-261M | $-247M | |
| Treasury Stock | · | · | · | · | · | · | · | $0 | $51.0K | $51.0K | $51.0K | $51.0K | |
| AOCI | $575.0K | $82.0K | $135.0K | $-83.0K | $18.0K | $-104.0K | $28.0K | $50.0K | $42.0K | $-41.0K | $-8.0K | $20.0K | |
| Stockholders' Equity | $111M | $69M | $16M | $-6M | $12M | $22M | $-6M | $-15M | $678.0K | $-1M | $9M | $18M | |
| Liabilities + Equity | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Shares Outstanding | 34,691,671 | 33,061,002 | 22,761,554 | 10,046,571 | 7,906,728 | 5,996,101 | 67,091 | 14,715 | 228,139 | 11,750 | 1,360,239 | 9,708,841 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $23M | $-19M | $-31M | $-25M | $-23M | $-23M | $-24M | $-15M | $-15M | $-14M | $-16M | $-16M | |
| CapEx | $2M | $559.0K | $58.0K | $209.0K | $143.0K | $782.0K | $24.0K | $76.0K | $524.0K | $258.0K | $170.0K | $44.0K | |
| Investing Cash Flow | $-27M | $-981.0K | $-20M | $-209.0K | $-143.0K | $-782.0K | $-24.0K | $-76.0K | $-524.0K | · | · | · | |
| Net Debt Issued | · | $-11M | $-6M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $481.0K | $250.0K | $123.0K | $0 | $2M | $230.0K | $0 | $11M | · | · | · | · | |
| Stock Repurchased | $6M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-6M | $250.0K | $123.0K | · | $2M | $230.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $15M | $39M | $52M | $10M | $21M | $42M | $30M | $13M | $-11M | · | · | · | |
| Net Change in Cash | $11M | $20M | $874.0K | $-15M | $-2M | $19M | $7M | $-2M | $-26M | $-8M | $-8M | $-11M | |
| Taxes Paid | $2M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $21M | $-19M | $-31M | $-25M | $-23M | $-24M | $-24M | $-15M | · | · | $-17M | $-16M |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.2% | 83.4% | 69.2% | 74.8% | · | · | · | · | · | · | 73.6% | 72.8% | |
| Operating Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| Net Margin | 3.2% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | -1625.9% | |
| Pretax Margin | 4.1% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | · | |
| EBITDA Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| ROA | 2.7% | -45.8% | -168.8% | -143.2% | -75.7% | -98.9% | -84.3% | -244.4% | · | · | -74.5% | -57.1% | |
| ROE | 2.5% | -68.2% | -235.5% | 657.5% | -216.7% | -190.6% | 70.5% | 194.1% | · | · | -109.9% | -72.0% | |
| ROIC | 0.46% | -18.1% | -242.0% | 577.8% | -205.3% | -96.5% | 313.2% | · | · | · | -176.8% | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 | 3.2 | 0.8 | 0.3 | · | · | 2.3 | 4.8 | |
| Quick Ratio | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 | 2.9 | 0.6 | 0.2 | · | · | 2.0 | 4.5 |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.9 | 0.6 | 0.1 | 0.1 | · | · | · | · | · | · | 0.1 | 0.0 | |
| Inventory Turnover | 1.4 | 1.2 | 0.2 | 0.4 | 0.6 | 0.8 | 1.0 | 1.0 | · | · | 0.8 | 0.5 | |
| Receivables Turnover | 7.5 | 6.7 | 6.8 | 13.3 | · | · | · | · | · | · | 7.7 | 4.1 |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.21 | $2.08 | $0.69 | $-0.74 | $1.51 | $3.68 | $-94.75 | $-1.46 | · | · | $0.40 | $1.87 | |
| Revenue / Share | $2.14 | $1.30 | $0.13 | $0.31 | · | · | · | · | · | · | $0.11 | $0.11 | |
| Cash Flow / Share | $0.56 | $-0.66 | $-1.93 | $-2.81 | · | $-7.89 | · | $-0.55 | · | · | $-1.02 | $-1.65 | |
| Cash / Share | $1.25 | $0.98 | $0.56 | $0.97 | $2.88 | $4.77 | $149.08 | $0.25 | · | · | $0.58 | $2.11 | |
| EPS (TTM) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 129.1% | 1701.7% | -24.1% | -23.5% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 215.3% | 118.7% | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $85M | $37M | $2M | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | |
| Net Income TTM | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Market Cap | $350M | $398M | $95M | $28M | $61M | $107M | $1M | $2.01B | · | · | · | · | |
| P/E | 144.3 | -12.9 | -1.4 | -0.9 | -2.2 | -2.1 | -0.1 | -272.2 | · | · | · | · | |
| P/S | 4.1 | 10.7 | 45.9 | 10.5 | 17.2 | 34.8 | 0.5 | 649.3 | · | · | · | · | |
| P/B | 3.2 | 5.8 | 6.0 | -4.9 | 5.1 | 4.9 | -0.2 | -134.2 | · | · | · | · | |
| P / Tangible Book | 3.2 | 5.8 | 6.0 | · | 5.1 | 4.9 | · | · | · | · | · | · | |
| P / Cash Flow | 15.6 | -21.3 | -3.0 | -1.1 | -2.7 | -4.7 | -0.1 | -136.1 | · | · | · | · | |
| P / FCF | 16.7 | -20.7 | -3.0 | -1.1 | -2.7 | -4.5 | -0.1 | -135.4 | · | · | · | · | |
| Earnings Yield | 0.69% | -7.7% | -70.7% | -114.4% | -46.3% | -46.6% | -1613.3% | -0.37% | · | · | · | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $25M | $21M | $21M | $24M | $20M | $15M | $11M | $8M | $3M | $539.0K | $434.0K | $495.0K | $597.0K | $638.0K | $906.0K | |
| Cost of Revenue | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $903.0K | $171.0K | $133.0K | $150.0K | $181.0K | $238.0K | $235.0K | |
| Gross Profit | $26M | $21M | $18M | $18M | $21M | $17M | $13M | $10M | $6M | $2M | $368.0K | $301.0K | $345.0K | $416.0K | $400.0K | $671.0K | |
| R&D Expense | $10M | $10M | $9M | $8M | $7M | $5M | $3M | $4M | $3M | $4M | $5M | $5M | $4M | $5M | $4M | $4M | |
| SG&A Expense | $13M | $13M | $11M | $10M | $11M | $11M | $7M | $7M | $7M | $9M | $7M | $6M | $5M | $4M | $4M | $5M | |
| Operating Expenses | $24M | $23M | $20M | $18M | $18M | $16M | $10M | $11M | $10M | $13M | $12M | $11M | $8M | $9M | $8M | $9M | |
| Operating Income | $2M | $-2M | $-2M | $-388.0K | $3M | $642.0K | $3M | $-1M | $-4M | $-10M | $-11M | $-11M | $-8M | $-8M | $-8M | $-8M | |
| Other Non-op | $-17.0K | $-58.0K | $-7.0K | $-33.0K | $-34.0K | $4.0K | $-53.0K | $35.0K | $10.0K | $-22.0K | $-73.0K | $-5.0K | $6.0K | $13.0K | $27.0K | $26.0K | |
| Pretax Income | $3M | $-908.0K | $-1M | $375.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | · | · | · | · | · | · | |
| Income Tax | $491.0K | $162.0K | $562.0K | $-455.0K | $508.0K | $195.0K | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $3M | $-1M | $-2M | $830.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | $-11M | $-20M | $-7M | $-9M | $-8M | $-9M | |
| EPS (Basic) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.08 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| EPS (Diluted) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.07 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| Shares (Basic) | 35,891,915 | 36,021,210 | · | 36,383,277 | 35,786,813 | 34,642,641 | · | 28,738,307 | 28,364,731 | 24,887,180 | · | 17,863,078 | 12,463,665 | 11,622,384 | · | 9,215,786 | |
| Shares (Diluted) | 39,761,480 | 36,021,210 | · | 40,056,814 | 40,262,764 | 39,511,120 | · | 32,345,672 | 28,364,731 | 24,887,180 | · | 17,863,078 | 12,463,665 | 11,622,384 | · | 9,215,786 | |
| EBITDA | $2M | $-2M | · | $-388.0K | $3M | $642.0K | · | $-1M | $-4M | $-10M | · | $-11M | $-8M | $-8M | · | $-8M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $41M | $43M | $42M | $34M | $13M | $32M | $8M | $15M | $12M | $13M | $40M | $15M | $24M | $8M | $10M | |
| Receivables | $16M | $14M | $12M | $14M | $16M | $14M | $11M | $7M | $4M | $2M | $241.0K | $205.0K | $127.0K | $458.0K | $366.0K | $537.0K | |
| Inventory | $12M | $10M | $10M | $11M | $11M | $7M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | |
| Prepaid Expense | $7M | $7M | $6M | $7M | $6M | $4M | $3M | $1M | $1M | $1M | $1M | $3M | $2M | $2M | $2M | $2M | |
| Current Assets | $131M | $120M | $120M | $121M | $113M | $84M | $74M | $29M | $31M | $34M | $37M | $46M | $19M | $29M | $16M | $18M | |
| PP&E (Net) | $4M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| PP&E (Gross) | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $7M | $7M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| Total Assets | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Accounts Payable | $4M | $3M | $3M | $2M | $5M | $2M | $961.0K | $937.0K | $3M | $1M | $1M | $753.0K | $966.0K | $2M | $2M | $3M | |
| Accrued Liabilities | $9M | $7M | $8M | $6M | $6M | $4M | $5M | $6M | $4M | $4M | $5M | $5M | $6M | $7M | $5M | $5M | |
| Current Liabilities | $13M | $11M | $11M | $8M | $10M | $5M | $6M | $22M | $12M | $13M | $16M | $14M | $11M | $13M | $15M | $14M | |
| Capital Leases | $2M | $815.0K | $835.0K | $855.0K | $877.0K | $906.0K | $933.0K | $963.0K | $989.0K | $1M | $0 | · | · | · | · | · | |
| Other Non-current Liabilities | $327.0K | $615.0K | $628.0K | $582.0K | $578.0K | $896.0K | $766.0K | $563.0K | $632.0K | $962.0K | $840.0K | $1M | $1M | $1M | $1M | $1M | |
| Total Liabilities | $16M | $12M | $12M | $9M | $12M | $7M | $8M | $23M | $30M | $21M | $23M | $23M | $21M | $25M | $24M | $25M | |
| Long-term Debt | · | · | · | · | · | · | · | $2M | $4M | $7M | $10M | · | · | · | $16M | · | |
| Common Stock | $346.0K | $344.0K | $347.0K | $353.0K | $350.0K | $334.0K | $331.0K | $280.0K | $279.0K | $254.0K | $228.0K | $197.0K | $153.0K | $101.0K | $100.0K | $86.0K | |
| Paid-in Capital | $648M | $642M | $639M | $641M | $632M | $610M | $600M | $536M | $534M | $530M | $521M | $519M | $473M | $453M | $452M | $442M | |
| Retained Earnings | $-527M | $-530M | $-529M | $-527M | $-528M | $-530M | $-532M | $-528M | $-530M | $-516M | $-505M | $-494M | $-474M | $-466M | $-457M | $-447M | |
| AOCI | $258.0K | $571.0K | $575.0K | $875.0K | $592.0K | $381.0K | $82.0K | $11.0K | $8.0K | $157.0K | $135.0K | $-59.0K | $-64.0K | $-64.0K | $-83.0K | $-57.0K | |
| Stockholders' Equity | $121M | $113M | $111M | $115M | $105M | $80M | $69M | $9M | $4M | $15M | $16M | $25M | $-242.0K | $-13M | $-6M | $-5M | |
| Liabilities + Equity | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Shares Outstanding | 34,636,252 | 34,465,087 | 34,691,671 | 35,308,939 | 34,955,974 | 33,436,612 | 33,061,002 | 28,019,599 | 27,931,393 | 25,439,319 | 22,761,554 | 19,688,991 | 15,250,469 | 10,046,571 | 10,046,571 | 8,597,682 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6M | $857.0K | $8M | $5M | $7M | $2M | $-1M | $-4M | $-4M | $-10M | $-8M | $-9M | $-10M | $-4M | $-7M | $-5M | |
| CapEx | $503.0K | $570.0K | $550.0K | $459.0K | $398.0K | $140.0K | $229.0K | $216.0K | $101.0K | $13.0K | $19.0K | $-1.0K | $40.0K | $0 | $0 | $68.0K | |
| Investing Cash Flow | $-504.0K | $-571.0K | $-561.0K | $-466.0K | $-415.0K | $-25M | $-15M | $-697.0K | $10M | $5M | $-20M | $1.0K | $-40.0K | $0 | $0 | $-68.0K | |
| Stock Issued | $0 | $389.0K | $0 | $243.0K | $0 | $238.0K | $0 | $175.0K | $0 | $75.0K | $0 | $76.0K | $0 | $47.0K | $0 | $0 | |
| Stock Repurchased | $11.0K | $3M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $-3M | · | · | · | $238.0K | · | · | · | $75.0K | · | · | · | $47.0K | · | · | |
| Financing Cash Flow | $962.0K | $-2M | $-6M | $3M | $15M | $3M | $40M | $-2M | $-3M | $4M | $1.0K | $35M | $7.0K | $17M | $5M | $5M | |
| Net Change in Cash | $6M | $-2M | $2M | $7M | $22M | $-20M | $24M | $-6M | $3M | $-886.0K | $-28M | $26M | $-10M | $12M | $-2M | $-372.0K | |
| Taxes Paid | · | · | $228.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $287.0K | · | · | · | $2M | · | · | · | $-10M | · | · | · | $-4M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.8% | 85.0% | · | 87.2% | 86.3% | 85.6% | · | 85.4% | 80.4% | 71.2% | · | 69.3% | 69.7% | 69.7% | · | · | |
| Operating Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| Net Margin | 9.2% | -4.3% | · | 4.0% | 11.2% | 5.4% | · | 16.6% | -176.9% | -354.0% | · | -4686.6% | -1455.0% | -1507.5% | · | · | |
| Pretax Margin | 10.8% | -3.6% | · | 1.8% | 13.3% | 6.4% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| ROA | 2.1% | -1.0% | · | 1.1% | 3.6% | 1.7% | · | 4.7% | -50.0% | -33.3% | · | -60.0% | -34.2% | -31.1% | · | -31.1% | |
| ROE | 2.4% | -1.1% | · | 1.4% | 4.9% | 2.2% | · | 11.2% | -695.8% | -1439.2% | · | -208.9% | 466.5% | 229.3% | · | -262.5% | |
| ROIC | 1.7% | -1.7% | · | -0.75% | 2.1% | 0.68% | · | · | · | · | · | · | · | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.8 | 11.2 | · | 15.1 | 10.9 | 16.0 | · | 1.3 | 2.6 | 2.5 | · | 3.3 | 1.8 | 2.2 | · | 1.3 | |
| Quick Ratio | 4.8 | 5.2 | · | 6.9 | 4.8 | 5.1 | · | 0.7 | 1.5 | 1.0 | · | 2.9 | 1.3 | 1.8 | · | 0.7 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | · | |
| Inventory Turnover | 0.3 | 0.4 | · | 0.3 | 0.4 | 0.5 | · | 0.4 | 0.3 | 0.3 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.8 | 1.8 | · | 2.0 | 2.5 | 2.6 | · | 3.1 | 4.0 | 3.1 | · | 1.2 | 1.8 | 1.9 | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.50 | $3.27 | · | $3.25 | $3.00 | $2.40 | · | $0.31 | $0.15 | $0.57 | · | $1.26 | $-0.02 | $-1.30 | · | $-0.61 | |
| Revenue / Share | $0.73 | $0.69 | · | $0.51 | $0.60 | $0.50 | · | $0.35 | $0.27 | $0.13 | · | $0.02 | $0.04 | $0.05 | · | · | |
| Cash Flow / Share | · | $0.02 | · | · | · | $0.06 | · | · | · | $-0.39 | · | · | · | $-0.37 | · | · | |
| Cash / Share | $1.37 | $1.20 | · | $1.18 | $0.98 | $0.38 | · | $0.30 | $0.53 | $0.46 | · | $2.06 | $0.95 | $2.41 | · | $1.14 | |
| EPS (TTM) | $0.01 | $0.01 | · | $0.06 | $0.10 | $-0.45 | · | $-1.32 | $-2.52 | $-2.62 | · | $-3.31 | $-3.13 | $-3.79 | · | $-3.95 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $95M | $90M | · | $80M | $70M | $54M | · | $23M | $12M | $5M | · | $2M | $3M | $3M | · | · | |
| Net Income TTM | $532.0K | $561.0K | · | $1M | $2M | $-14M | · | $-34M | $-56M | $-50M | · | $-45M | $-34M | $-37M | · | $-33M | |
| Market Cap | $436M | $320M | · | $380M | $475M | $426M | · | $253M | $234M | $121M | · | $80M | $89M | $58M | · | $28M | |
| P/E | 1259.0 | 928.0 | · | 179.2 | 136.0 | -28.3 | · | -6.8 | -3.3 | -1.8 | · | -1.2 | -1.9 | -1.5 | · | -0.8 | |
| P/S | 4.6 | 3.5 | · | 4.8 | 6.8 | 7.9 | · | 11.2 | 19.7 | 26.3 | · | 36.8 | 33.7 | 19.7 | · | · | |
| P/B | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | -367.4 | -4.4 | · | -5.2 | |
| P / Tangible Book | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | · | · | · | · | |
| P / Cash Flow | · | 373.2 | · | · | · | 193.2 | · | · | · | -12.7 | · | · | · | -13.5 | · | · | |
| Earnings Yield | 0.08% | 0.11% | · | 0.56% | 0.74% | -3.5% | · | -14.6% | -30.1% | -54.9% | · | -81.7% | -53.7% | -65.9% | · | -123.4% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $85M | $37M | $2M | $3M | $4M |
| 毛利率 % | 86.2% | 83.4% | 69.2% | 74.8% | · |
| 营业利润率 % | 0.77% | -33.4% | -1849.0% | -1245.0% | · |
| 净收入 | $3M | $-26M | $-48M | $-37M | $-26M |
| 稀释后每股收益 (EPS) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流动比率 | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 |
| 速动比率 | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $21M | $-19M | $-31M | $-25M | $-23M |
机构持有人 (13F) 139 家申报者 · $243.2M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
139
持有价值
$243.2M
新仓位
21
已退出持仓
17
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 21 (-10 与上一季度对比) | 17 (-3 与上一季度对比) | 48 (+10 与上一季度对比) | 29 (-8 与上一季度对比) | +1.1M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | $41551898 | 3300389 | 17.08% | 股份 |
| BlackRock, Inc. | $34078638 | 2706802 | 14.01% | 股份 |
| VANGUARD GROUP INC | $16890806 | 1672357 | 6.94% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $15375500 | 1221247 | 6.32% | 股份 |
| Propel Bio Management, LLC | $10971681 | 871460 | 4.51% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $9232592 | 733115 | 3.80% | 股份 |
| STATE STREET CORP | $8552135 | 679280 | 3.52% | 股份 |
| ALGERT GLOBAL LLC | $7311114 | 580708 | 3.01% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $7130611 | 566371 | 2.93% | 股份 |
| Divisadero Street Capital Management, LP | $6292432 | 499796 | 2.59% | 股份 |
| MORGAN STANLEY | $5136506 | 407983 | 2.11% | 股份 |
| ExodusPoint Capital Management, LP | $4530940 | 359884 | 1.86% | 股份 |
| Private Wealth Advisors, LLC | $3913765 | 310863 | 1.61% | 股份 |
| Simplify Asset Management Inc. | $3333454 | 264770 | 1.37% | 股份 |
| NORTHERN TRUST CORP | $3174040 | 252108 | 1.30% | 股份 |
| GOLDMAN SACHS GROUP INC | $3151429 | 250312 | 1.30% | 股份 |
| ADAR1 Capital Management, LLC | $2825007 | 224385 | 1.16% | 股份 |
| MARSHALL WACE, LLP | $2756745 | 218963 | 1.13% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $2647652 | 210298 | 1.09% | 股份 |
| KENNEDY CAPITAL MANAGEMENT LLC | $2570160 | 204143 | 1.06% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2435510 | 193448 | 1.00% | 股份 |
| Ikarian Capital, LLC | $2337548 | 185667 | 0.96% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $2290159 | 181903 | 0.94% | 股份 |
| Nuveen, LLC | $2286281 | 181595 | 0.94% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $2177981 | 172993 | 0.90% | 股份 |
| CIBC WORLD MARKET INC. | $2054789 | 163208 | 0.84% | 股份 |
| Caption Management, LLC | $1894795 | 150500 | 0.78% | 卖出期权 |
| Lane Generational LLC | $1884257 | 149663 | 0.77% | 股份 |
| HSBC HOLDINGS PLC | $1705848 | 135600 | 0.70% | 股份 |
| Man Group plc | $1617752 | 128495 | 0.67% | 股份 |
| Cubist Systematic Strategies, LLC | $1562514 | 145350 | 0.64% | 股份 |
| Diametric Capital, LP | $1546568 | 122841 | 0.64% | 股份 |
| Bank of New York Mellon Corp | $1361725 | 108159 | 0.56% | 股份 |
| BARCLAYS PLC | $1359090 | 107950 | 0.56% | 股份 |
| Caption Management, LLC | $1259000 | 100000 | 0.52% | 买入期权 |
| Capital Advisors Wealth Management, LLC | $1170870 | 93000 | 0.48% | 股份 |
| Jump Financial, LLC | $1108360 | 88035 | 0.46% | 股份 |
| Jefferies Financial Group Inc. | $1057308 | 83980 | 0.43% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1050824 | 83465 | 0.43% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1022308 | 81200 | 0.42% | 买入期权 |
| Stonepine Capital Management, LLC | $1000000 | 100000 | 0.41% | 买入期权 |
| Caption Management, LLC | $978243 | 77700 | 0.40% | 股份 |
| Russell Investments Group, Ltd. | $851813 | 67658 | 0.35% | 股份 |
| FOX RUN MANAGEMENT, L.L.C. | $776526 | 61678 | 0.32% | 股份 |
| BANK OF AMERICA CORP /DE/ | $774587 | 61524 | 0.32% | 股份 |
| Quantbot Technologies LP | $749860 | 59560 | 0.31% | 股份 |
| D. E. Shaw & Co., Inc. | $728885 | 57894 | 0.30% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $725864 | 57654 | 0.30% | 股份 |
| Creative Planning | $609784 | 48434 | 0.25% | 股份 |
| UBS Group AG | $525179 | 41714 | 0.22% | 股份 |
激进投资者及 5%+ 股东 17 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc., SALAMON STEVEN A J, Aharon Gil, Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P. ×15 申报 | 2026年2月10日 | 9.90% | 修订 | · | SEC |
| 未披露的报告人 | 2022年12月16日 | · | 初始申报 | 被动投资 | SEC |
| 未披露的报告人 | 2022年7月27日 | · | 初始申报 | 被动投资 | SEC |
| Laddcap Value Partners LP S.S. or, Laddcap Value Associates LLC S.S. or, Laddcap Value Advisors LLC S.S. or, Robert Ladd S.S. or ×2 申报 | 2010年8月2日 | · | 初始申报 | · | SEC |
| Robert Ladd | 2006年10月18日 | · | 初始申报 | 被动投资 | SEC |
| 未披露的报告人 | 2006年7月28日 | · | 初始申报 | 董事会活动 | SEC |
| 未披露的报告人 | 2006年7月11日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2006年6月14日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2006年6月8日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2006年5月24日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2006年4月28日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2006年1月10日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2006年1月6日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2005年12月14日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2005年11月10日 | · | 初始申报 | 董事会活动 | SEC |
| 未披露的报告人 | 2005年10月24日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2005年10月17日 | · | 初始申报 | 被动投资 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 49 位内幕人士 · 13 位高管 · 17 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Jennifer K. Simpson | President and CEO | 2020年5月8日 C | 25021 | 0 | 0 | $0 |
| Sandra Pennell | Chief Financial Officer | 2026年3月6日 P | 77018 | 1 | 0 | $50018 |
| Barbra Keck | Chief Financial Officer, Secretary | 2020年5月8日 C | 12851 | 0 | 0 | $0 |
| Paul M Feinstein | Chief Financial Officer | 2007年11月30日 A | 3375 | 0 | 0 | $0 |
| Martha S. Rook | CHIEF OPERATING OFFICER | 2026年2月17日 A | · | 0 | 0 | $0 |
| John Purpura | CHIEF OPERATING OFFICER | 2023年2月8日 A | 41526 | 0 | 0 | $0 |
| HERSCHKOWITZ SAMUEL /FA/ | Chief Operating Officer | 2007年5月29日 P | 160375 | 0 | 0 | $0 |
| David L. Hoffman | GEN'L COUNSEL, CCO & SECY | 2026年2月17日 A | 74330 | 0 | 0 | $0 |
| Kevin Muir | GM INTERVENTIONAL ONCOLOGY | 2026年2月17日 A | 18582 | 0 | 0 | $0 |
| Vojo Vukovic | CHIEF MEDICAL OFFICER | 2026年2月17日 A | 168882 | 0 | 0 | $0 |
| Johnny John | SVP CLINICAL DEV & MED AFFAIRS | 2023年2月8日 A | · | 0 | 0 | $0 |
| Anthony Dias | VP FINANCE | 2023年2月8日 A | · | 0 | 0 | $0 |
| Christine Padula | Interim Principal Accounting Officer | 2021年9月1日 A | · | 0 | 0 | $0 |
| Aharon Gil | 董事 | 2026年5月13日 A | 3413468 | 0 | 0 | $0 |
| John Richard Sylvester | 董事 | 2026年5月13日 A | 14936 | 1 | 0 | $38992 |
| Bridget A Martell | 董事 | 2026年5月13日 A | · | 0 | 0 | $0 |
| Steven A J Salamon | 董事 | 2026年5月13日 A | 3413468 | 0 | 0 | $0 |
| Roger G Stoll PHD | 董事 | 2024年5月23日 A | 9309 | 0 | 0 | $0 |
| Rosalind Advisors, Inc. | 董事 | 2022年12月14日 P | 459315 | 0 | 0 | $0 |
| Marco Taglietti | 董事 | 2020年5月8日 C | 6000 | 0 | 0 | $0 |
| William Dodge Rueckert | 董事 | 2020年5月8日 C | 6014 | 0 | 0 | $0 |
| Simon Pedder | 董事 | 2019年2月1日 A | · | 0 | 0 | $0 |
| Laura A Philips | 董事 | 2015年7月23日 P | 205299 | 0 | 0 | $0 |
| Harold S Koplewicz | 董事 | 2015年6月10日 A | 45052 | 0 | 0 | $0 |
| Dennis Langer | 董事 | 2015年6月10日 A | 20000 | 0 | 0 | $0 |
| Jonathan Lewis | 董事 | 2008年6月30日 A | 10000 | 0 | 0 | $0 |
| Mark Corigliano | 董事 | 2007年4月16日 M | 198176 | 0 | 0 | $0 |
| Daniel Isdaner | 董事 | 2007年4月16日 M | 253668 | 0 | 0 | $0 |
| Elizabeth Czerepak | · | 2026年5月13日 A | · | 0 | 0 | $0 |
| Gerard J Michel | · | 2026年3月2日 P | 342034 | 2 | 0 | $198447 |
| Laura Brege | · | 2014年7月7日 A | 11678 | 0 | 0 | $0 |
| Tasos Konidaris | · | 2014年7月7日 A | 11678 | 0 | 0 | $0 |
| Gabriel Leung | · | 2014年7月7日 A | 21485 | 0 | 0 | $0 |
| Douglas G Watson | · | 2014年7月7日 A | 136664 | 0 | 0 | $0 |
| Graham G Miao | · | 2013年11月14日 A | 54000 | 0 | 0 | $0 |
| Peter J Graham | · | 2013年11月14日 A | 15000 | 0 | 0 | $0 |
| William M Appling | · | 2013年7月15日 A | · | 0 | 0 | $0 |
| Krishna Kandarpa | · | 2013年3月11日 A | 159000 | 0 | 0 | $0 |
| Harold Mapes | · | 2013年3月11日 A | 17000 | 0 | 0 | $0 |
| Eamonn P Hobbs | · | 2013年3月11日 A | 162000 | 0 | 0 | $0 |
| Agustin V Gago | · | 2013年3月11日 A | 80944 | 0 | 0 | $0 |
| Robert Ladd | · | 2012年6月15日 A | 69534 | 0 | 0 | $0 |
| David Mcdonald | · | 2011年3月10日 A | 47706 | 0 | 0 | $0 |
| Pamela Reilly Contag | · | 2010年12月1日 A | 8507 | 0 | 0 | $0 |
| Richard Taney | · | 2009年12月10日 A | 211485 | 0 | 0 | $0 |
| Jason Andrew Rifkin | · | 2009年10月12日 A | · | 0 | 0 | $0 |
| KOLY M S /FA/ | · | 2007年1月26日 X | 775360 | 0 | 0 | $0 |
| Victor Nevins | · | 2006年10月12日 M | 180007 | 0 | 0 | $0 |
| VENKOL TRUST | · | 2004年11月10日 J | 892649 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 16 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| IWC · iShares Trust | 0.11% | 97206 SH | 2026年9月11日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 21358 SH | 2026年8月19日 | 每日 |
| IWM · iShares Trust | 0.02% | 743359 SH | 2026年9月11日 | 每日 |
| OMFS · Invesco Exchange-Traded Self-Inde... | 0.01% | 2376 SH | 2026年10月2日 | 每日 |
| RSSL · Global X Funds | 0.01% | 13736 NS | 2026年7月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 165177 SH | 2026年8月19日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.01% | 70373 NS | 2026年7月31日 | N-PORT |
| IWO · iShares Trust | 0.00% | 39522 SH | 2026年9月11日 | 每日 |
| DFSU · Dimensional ETF Trust | 0.00% | 3297 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 43746 SH | 2026年9月11日 | 每日 |
| DFAC · Dimensional ETF Trust | 0.00% | 12489 NS | 2026年7月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 304809 SH | 2026年8月19日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 889410 SH | 2026年8月19日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.00% | 4438 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2475 SH | 2026年8月19日 | 每日 |
| IWN · iShares Trust | · | 228409 SH | 2026年9月11日 | 每日 |
DCTH 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 12 位分析师
买入
中位数目标
$22.00
+45.4%
3 25.0%
强烈买入
8 66.7%
买入
1 8.3%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
5 位分析师 · 2026-09-29平均目标 $24.00 +58.6%
← 低于所有目标
当前价格 $15.13
最低$21.00
平均值$24.00
最高$32.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| DCTH | $350M | 144.3 | 129.1% | 3.2% | 2.5% | 86.2% |
| SSII | · | -94.7 | 105.7% | · | · | · |
| SENS | $228M | -3.3 | 56.9% | -196.0% | -88.7% | 44.7% |
| TCMD | $651M | 35.4 | 12.5% | 5.8% | 9.2% | 75.9% |
| SGHT | $424M | -10.7 | -3.1% | -49.7% | -57.4% | 86.2% |
| NPCE | $518M | -23.4 | 25.1% | -21.5% | -111.6% | 77.2% |
| SI | $295M | -3.1 | 49.6% | -85.3% | -129.1% | 76.5% |
| CARL | $329M | -5.8 | 85.9% | -58.7% | -375.2% | 75.3% |
| OFIX | $604M | -6.5 | 2.9% | -11.2% | -20.3% | 68.8% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 6, 2026 申报